Company / Free Cash Flow
ResMed Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$1.7B
FY2025
5-year range
$216.3M / $1.7B
FY2021-FY2025
Trend
+27.6%
vs FY2024
Sector context
#17 of 145
Health Care
What the data says
ResMed's free cash flow of $1.7B is higher than 88% of companies in the Health Care sector (FY2025). Free Cash Flow has increased for 3 consecutive years, from $216M in FY2022 to $1.7B in FY2025.
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of +18.6%. Top quartile in the Health Care sector.
Improved from $574M to $1.7B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +97.3%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 145This company $1.7B Sector average $770.9M
▼
+115.6% above sector average
Key checks
Key Insights
- ResMed's free cash flow has grown for 3 consecutive years.
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, free cash flow increased 27.6% year-over-year.
- Ranks #17 out of 145 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | +27.6% |
| FY2024 | $1.3B | +126.9% |
| FY2023 | $573.6M | +165.2% |
| FY2022 | $216.3M | -65.9% |
| FY2021 | $634.0M | -10.3% |
| FY2020 | $706.9M | +81.1% |
| FY2019 | $390.3M | -11.8% |
| FY2018 | $442.4M | +25.8% |
| FY2017 | $351.8M | -28.1% |
| FY2016 | $489.4M | +52.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026